Top Markets
Coin of the day
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCI
株式のランク #37527
Intellipharmaceutics International Inc., founded in Toronto, Canada, in 1998,... Intellipharmaceutics International Inc., founded in Toronto, Canada, in 1998, is a pharmaceutical company that focuses on the research, development, and manufacturing of innovative and generic controlled-release and targeted-release oral solid dosage medications, primarily for the United States market. The company leverages its patented Hypermatrix technology to create advanced drug delivery systems, an array of product candidates, and a robust pipeline across diverse therapeutic areas, including neurological, cardiovascular, gastrointestinal, diabetes, and pain management conditions. Its current product portfolio includes extended-release formulations like Focalin XR for hyperactivity disorder, Keppra XR for partial onset seizures, Effexor XR to treat depression, and Protonix for gastroesophageal reflux disease. Other offerings feature Glucophage XR for type 2 diabetes, Seroquel XR for schizophrenia and mood disorders, Lamictal XR for epilepsy, Pristiq for depression, Coreg CR for heart failure and hypertension, and Ranexa for chronic angina. Furthermore, Intellipharmaceutics is actively developing additional controlled-release drugs such as OxyContin for pain relief and Regabatin XR for neuropathic pain management. The company operates under a license and commercialization agreement with Par Pharmaceutical Inc.
株価
$0.05897422
最終同期: 2024-04-02
時価総額
$1.64M
変化(1日)
0.07%
変化(1年)
0.00%
CA
取引 Intellipharmaceutics International Inc. (IPCI)

カテゴリー

Intellipharmaceutics International Inc.(IPCI)の利益
2026 時点の利益 TTM: 0
Intellipharmaceutics International Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Intellipharmaceutics International Inc. の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益